🚀 VC round data is live in beta, check it out!
Largest Public Companies in Israel
Benchmark revenue and EBITDA valuation multiples for public comps like
Teva Pharmaceuticals, Elbit Systems, Bank Leumi, Bank Hapoalim and Mizrahi-Tefahot Bank.
 | $33 | +120% | $39B | $52B | 3.1x | 9.9x | ||
| $809 | +110% | $38B | $38B | 4.7x | 41.9x | ||
| $25 | +52% | $36B | $51B | 6.8x | — | ||
| $26 | +63% | $35B | $41B | 5.2x | — | ||
| $76 | +41% | $20B | $33B | 7.0x | — | ||
| $146 | +81% | $18B | $26B | 26.7x | 31.0x | ||
| $158 | -31% | $17B | $16B | 5.8x | 13.8x | ||
| $12 | +47% | $15B | $22B | 4.5x | — | ||
| $125 | +256% | $14B | $13B | 8.1x | 25.0x | ||
| $52 | +133% | $13B | $8B | 2.5x | — | ||
| $53 | +177% | $11B | $8B | 1.6x | — | ||
| $116 | +322% | $11B | $10B | 53.7x | 87.0x | ||
| $69 | +261% | $10B | $14B | — | — | ||
| $145 | +141% | $9B | $10B | — | — | ||
| $87 | +44% | $9B | $11B | — | — | ||
| $29 | +175% | $9B | $9B | — | — | ||
| $3 | +60% | $8B | $10B | 3.6x | 8.3x | ||
| $126 | -18% | $8B | $7B | 2.5x | 7.4x | ||
| $6 | +56% | $7B | $9B | 9.5x | 11.8x | ||
| $8 | -41% | $7B | $5B | 2.8x | 16.4x | ||
| $137 | +47% | $7B | $11B | — | — | ||
| $261 | +57% | $7B | $14B | — | — | ||
| $5 | -25% | $7B | $9B | 1.2x | 5.9x | ||
| $80 | +173% | $6B | $9B | — | — | ||
| $6 | +172% | $6B | ($3B) | — | — | ||
| $336 | +81% | $6B | $9B | — | — | ||
| $143 | +311% | $5B | $7B | — | — | ||
| $45 | +77% | $5B | $6B | — | — | ||
| $49 | +250% | $5B | $4B | 24.5x | — | ||
| $38 | +35% | $5B | $5B | — | — | ||
| $86 | +125% | $4B | $5B | — | — | ||
| $14 | +25% | $4B | $5B | — | — | ||
| $54 | +48% | $4B | $3B | 3.8x | 8.6x | ||
| $106 | +68% | $4B | $5B | — | — | ||
| $6 | +97% | $4B | $6B | — | — | ||
| $10 | +43% | $4B | $7B | — | — | ||
| $18 | +372% | $4B | $5B | — | — | ||
| $5 | +50% | $3B | $6B | — | — | ||
| $84 | +49% | $3B | $8B | — | — | ||
| $29 | +98% | $3B | $7B | 1.1x | 3.6x | ||
| $7 | +16% | $3B | $6B | — | — | ||
| $14 | -30% | $3B | $3B | 5.9x | 21.8x | ||
| $199 | +27% | $3B | $10B | — | — | ||
| $14 | +54% | $3B | $6B | — | — | ||
| $5 | +70% | $3B | $7B | — | — | ||
| $28 | +270% | $3B | $3B | — | — | ||
| $53 | +112% | $3B | $3B | — | — | ||
| $137 | +41% | $3B | $5B | — | — | ||
| $5 | +39% | $3B | $2B | — | — | ||
| $12 | +33% | $3B | $12B | — | — | ||
| $33 | -- | $3B | $2B | 1.7x | 4.7x | ||
| $249 | +56% | $3B | $4B | — | — | ||
| $3 | +303% | $2B | $3B | — | — | ||
| $259 | +69% | $2B | $3B | — | — | ||
| $22 | +34% | $2B | $7B | — | — | ||
| $31 | +10% | $2B | $4B | — | — | ||
| $12 | +52% | $2B | $3B | — | — | ||
| $6 | +70% | $2B | $5B | — | — | ||
| $13 | +74% | $2B | $3B | — | — | ||
| $7 | +37% | $2B | $3B | — | — | ||
| $33 | +17% | $2B | $2B | — | — | ||
| $54 | +96% | $2B | $3B | — | — | ||
| $18 | +5% | $2B | $3B | — | — | ||
| $261 | -19% | $2B | $4B | — | — | ||
| $19 | +253% | $2B | $2B | — | — | ||
| $51 | +25% | $2B | $2B | 4.4x | 28.2x | ||
| $50 | +18% | $2B | $4B | — | — | ||
| $31 | +58% | $2B | $2B | — | — | ||
| $119 | +15% | $2B | $2B | — | — | ||
| $87 | +48% | $2B | $4B | — | — | ||
| $130 | +51% | $2B | $2B | — | — | ||
| $1 | +5% | $2B | $2B | — | — | ||
| $123 | +61% | $2B | $2B | — | — | ||
| $144 | +50% | $2B | $3B | — | — | ||
| $1 | +19% | $2B | $2B | — | — | ||
| $11 | +58% | $2B | $2B | — | — | ||
| $5 | -10% | $2B | $2B | — | — | ||
| $139 | +42% | $2B | $1B | — | — | ||
| $7 | +38% | $1B | $3B | — | — | ||
| $65 | -12% | $1B | $1B | — | — | ||
| $54 | +20% | $1B | $5B | — | — | ||
| $20 | -12% | $1B | $1B | — | — | ||
| $20 | +18% | $1B | $2B | — | — | ||
| $12 | +59% | $1B | $2B | — | — | ||
| $99 | +1% | $1B | $3B | — | — | ||
| $272 | +7% | $1B | $2B | — | — | ||
| $49 | -14% | $1B | $2B | — | — | ||
| $16 | +68% | $1B | $2B | — | — | ||
| $9 | +106% | $1B | $1B | 3.1x | 14.1x | ||
| $19 | +39% | $1B | $2B | — | — | ||
| $56 | +102% | $1B | $2B | — | — | ||
| $95 | +31% | $1B | $2B | — | — | ||
| $12 | +32% | $1B | $3B | — | — | ||
| $1 | +53% | $1B | $2B | — | — | ||
| $62 | +11% | $1B | $1B | — | — | ||
| $74 | +47% | $1B | $1B | — | — | ||
| $3 | -46% | $1B | $3B | 1.1x | 3.9x | ||
| $7 | +41% | $1B | $1B | — | — | ||
| $0 | +16% | $1B | $2B | — | — | ||
| $11 | +13% | $980M | $2B | — | — |
![Isramco Negev 2 logo](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="20" height="20" viewBox="0 0 20 20"><rect fill="%23e5e7eb" width="20" height="20" rx="4"/></svg>)
Financial data powered by FactSet and Morningstar. Valuation multiples as of last 12 months. For more data, start your free trial here.
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.